Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2004;110:2349-2354
Published online before print October 11, 2004, doi: 10.1161/01.CIR.0000145167.30987.2E
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
110/16/2349    most recent
01.CIR.0000145167.30987.2Ev1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Latini, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Latini, R.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Medline Plus Health Information
*Heart Attack
Related Collections
Right arrow Acute myocardial infarction
Right arrow Other Vascular biology

(Circulation. 2004;110:2349-2354.)
© 2004 American Heart Association, Inc.


Coronary Heart Disease

Prognostic Significance of the Long Pentraxin PTX3 in Acute Myocardial Infarction

Roberto Latini, MD; Aldo P. Maggioni, MD; Giuseppe Peri, BS; Lucio Gonzini, BS; Donata Lucci, BS; Paolo Mocarelli, MD; Luca Vago, MD; Fabio Pasqualini, BS; Stefano Signorini, MD; Dario Soldateschi, BS; Lorenzo Tarli, BS; Carlo Schweiger, MD; Claudio Fresco, MD; Rossana Cecere, BS; Gianni Tognoni, MD; Alberto Mantovani, MD, on behalf of the Lipid Assessment Trial Italian Network (LATIN) Investigators

From the Mario Negri Institute for Pharmacological Research, Milan (R.L., G.P., F.P., A.M.); ANMCO Research Centre, Firenze (A.P.M., L.G., D.L.); Milano-Bicocca University, Department of Laboratory Medicine-Desio Hospital, Desio, Milan (P.M., S.S., R.C.); Department of Cardiac Rehabilitation, Passirana Hospital, Rho-Milano (C.S.); the Diesse–Diagnostica Senese SpA., Monteriggioni, Siena (D.S., L.T.); Institutes of Pathology and General Pathology (A.M.), University of Milan, L. Sacco Hospital, Milan (L.V.); Department of Cardiology, S. Maria della Misericordia Hospital, Udine (C.F.); and Consorzio Mario Negri Sud, S. Maria Imbaro, Chieti (G.T.), Italy.

Correspondence to Roberto Latini, Istituto di Ricerche Farmacologiche "Mario Negri," Via Eritrea, 62, 20157 Milano, Italy. E-mail latini{at}marionegri.it

Received January 8, 2004; de novo received April 19, 2004; revision received June 16, 2004; accepted June 21, 2004.

Background— Inflammation has a pathogenetic role in acute myocardial infarction (MI). Pentraxin-3 (PTX3), a long pentraxin produced in response to inflammatory stimuli and highly expressed in the heart, was shown to peak in plasma {approx}7 hours after MI. The aim of this study was to assess the prognostic value of PTX3 in MI compared with the best-known and clinically relevant biological markers.

Methods and Results— In 724 patients with MI and ST elevation, PTX3, C-reactive protein (CRP), creatine kinase (CK), troponin T (TnT), and N-terminal pro-brain natriuretic peptide (NT-proBNP) were assayed at entry, a median of 3 hours, and the following morning, a median of 22 hours from symptom onset. With respect to outcome events occurring over 3 months after the index event, median PTX3 values were 7.08 ng/mL in event-free patients, 16.12 ng/mL in patients who died, 9.12 ng/mL in patients with nonfatal heart failure, and 6.88 ng/mL in patients with nonfatal residual ischemia (overall P<0.0001). Multivariate analysis including CRP, CK, TnT, and NT-proBNP showed that only age ≥70 years (OR, 2.11; 95% CI, 1.04 to 4.31), Killip class >1 at entry (OR, 2.20; 95% CI, 1.14 to 4.25), and PTX3 (>10.73 ng/mL) (OR, 3.55; 95% CI, 1.43 to 8.83) independently predicted 3-month mortality. Biomarkers predicting the combined end point of death and heart failure in survivors were the highest tertile of PTX3 and of NT-proBNP and a CK ratio >6.

Conclusions— In a representative contemporary sample of patients with MI with ST elevation, the acute-phase protein PTX3 but not the liver-derived short pentraxin CRP or other cardiac biomarkers (NT-proBNP, TnT, CK) predicted 3-month mortality after adjustment for major risk factors and other acute-phase prognostic markers.


Key Words: C-reactive protein • myocardial infarction • natriuretic peptide, brain • troponin




This article has been cited by other articles:


Home page
CJASNHome page
M. E. Suliman, M. I. Yilmaz, J. J. Carrero, A. R. Qureshi, M. Saglam, O. M. Ipcioglu, M. Yenicesu, M. Tong, O. Heimburger, P. Barany, et al.
Novel Links between the Long Pentraxin 3, Endothelial Dysfunction, and Albuminuria in Early and Advanced Chronic Kidney Disease
Clin. J. Am. Soc. Nephrol., July 1, 2008; 3(4): 976 - 985.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
Z. Mallat and A. Tedgui
HDL, PTX3, and Vascular Protection
Arterioscler. Thromb. Vasc. Biol., May 1, 2008; 28(5): 809 - 811.
[Full Text] [PDF]


Home page
QJMHome page
M.E. Suliman, A.R. Qureshi, J.J. Carrero, P. Barany, M.I. Yilmaz, S. Snaedal-Jonsdottir, A. Alvestrand, O. Heimburger, B. Lindholm, and P. Stenvinkel
The long pentraxin PTX-3 in prevalent hemodialysis patients: associations with comorbidities and mortality
QJM, May 1, 2008; 101(5): 397 - 405.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
G. D. Norata, P. Marchesi, A. Pirillo, P. Uboldi, G. Chiesa, V. Maina, C. Garlanda, A. Mantovani, and A. L. Catapano
Long Pentraxin 3, a Key Component of Innate Immunity, Is Modulated by High-Density Lipoproteins in Endothelial Cells
Arterioscler. Thromb. Vasc. Biol., May 1, 2008; 28(5): 925 - 931.
[Abstract] [Full Text] [PDF]


Home page
Innate ImmunityHome page
H. Loppnow, K. Werdan, and M. Buerke
Invited review: Vascular cells contribute to atherosclerosis by cytokine- and innate-immunity-related inflammatory mechanisms
Innate Immunity, April 1, 2008; 14(2): 63 - 87.
[Abstract] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
C. Gustin, E. Delaive, M. Dieu, D. Calay, and M. Raes
Upregulation of Pentraxin-3 in Human Endothelial Cells After Lysophosphatidic Acid Exposure
Arterioscler. Thromb. Vasc. Biol., March 1, 2008; 28(3): 491 - 497.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
M. Salio, S. Chimenti, N. De Angelis, F. Molla, V. Maina, M. Nebuloni, F. Pasqualini, R. Latini, C. Garlanda, and A. Mantovani
Cardioprotective Function of the Long Pentraxin PTX3 in Acute Myocardial Infarction
Circulation, February 26, 2008; 117(8): 1055 - 1064.
[Abstract] [Full Text] [PDF]


Home page
CJASNHome page
M. Tong, J. J. Carrero, A. R. Qureshi, B. Anderstam, O. Heimburger, P. Barany, J. Axelsson, A. Alvestrand, P. Stenvinkel, B. Lindholm, et al.
Plasma Pentraxin 3 in Patients with Chronic Kidney Disease: Associations with Renal Function, Protein-Energy Wasting, Cardiovascular Disease, and Mortality
Clin. J. Am. Soc. Nephrol., September 1, 2007; 2(5): 889 - 897.
[Abstract] [Full Text] [PDF]


Home page
Nephrol Dial TransplantHome page
M. Boehme, F. Kaehne, A. Kuehne, W. Bernhardt, M. Schroder, W. Pommer, C. Fischer, H. Becker, C. Muller, and R. Schindler
Pentraxin 3 is elevated in haemodialysis patients and is associated with cardiovascular disease
Nephrol. Dial. Transplant., August 1, 2007; 22(8): 2224 - 2229.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
X. He, B. Han, and M. Liu
Long pentraxin 3 in pulmonary infection and acute lung injury
Am J Physiol Lung Cell Mol Physiol, May 1, 2007; 292(5): L1039 - L1049.
[Abstract] [Full Text] [PDF]


Home page
J. Exp. Med.Home page
S. Jaillon, G. Peri, Y. Delneste, I. Fremaux, A. Doni, F. Moalli, C. Garlanda, L. Romani, H. Gascan, S. Bellocchio, et al.
The humoral pattern recognition receptor PTX3 is stored in neutrophil granules and localizes in extracellular traps
J. Exp. Med., April 16, 2007; 204(4): 793 - 804.
[Abstract] [Full Text] [PDF]


Home page
Obstet GynecolHome page
P. Rovere-Querini, S. Antonacci, G. Dell'Antonio, A. Angeli, G. Almirante, E. D. Cin, L. Valsecchi, C. Lanzani, M. G. Sabbadini, C. Doglioni, et al.
Plasma and tissue expression of the long pentraxin 3 during normal pregnancy and preeclampsia.
Obstet. Gynecol., July 1, 2006; 108(1): 148 - 155.
[Abstract] [Full Text] [PDF]


Home page
J. Leukoc. Biol.Home page
B. Bottazzi, A. Bastone, A. Doni, C. Garlanda, S. Valentino, L. Deban, V. Maina, A. Cotena, F. Moalli, L. Vago, et al.
The long pentraxin PTX3 as a link among innate immunity, inflammation, and female fertility
J. Leukoc. Biol., May 1, 2006; 79(5): 909 - 912.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
P. Baruah, A. Propato, I. E. Dumitriu, P. Rovere-Querini, V. Russo, R. Fontana, D. Accapezzato, G. Peri, A. Mantovani, V. Barnaba, et al.
The pattern recognition receptor PTX3 is recruited at the synapse between dying and dendritic cells, and edits the cross-presentation of self, viral, and tumor antigens
Blood, January 1, 2006; 107(1): 151 - 158.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
B. Han, M. Mura, C. F. Andrade, D. Okutani, M. Lodyga, C. C. dos Santos, S. Keshavjee, M. Matthay, and M. Liu
TNF{alpha}-Induced Long Pentraxin PTX3 Expression in Human Lung Epithelial Cells via JNK
J. Immunol., December 15, 2005; 175(12): 8303 - 8311.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
M. Camozzi, S. Zacchigna, M. Rusnati, D. Coltrini, G. Ramirez-Correa, B. Bottazzi, A. Mantovani, M. Giacca, and M. Presta
Pentraxin 3 Inhibits Fibroblast Growth Factor 2-Dependent Activation of Smooth Muscle Cells In Vitro and Neointima Formation In Vivo
Arterioscler. Thromb. Vasc. Biol., September 1, 2005; 25(9): 1837 - 1842.
[Abstract] [Full Text] [PDF]